Introduction
Mouse skin carcinogenesis has been divided into three stages as an operational basis of understanding the multiple cellular and molecular alterations involved. The first stage, initiation, appears to involve mutational events. The second stage, promotion, involves epigenetic changes that contribute to the clonal expansion of the initiated cells. Tumor progression involves further genetic changes that allow for acquisition of malignant characteristics such as invasion, metastasis, angiogenesis and genetic instability (1).
Point mutations in the ras family of proto-oncogenes have been observed in human tumors (2) as well as in experimentally induced animal tumors (3) . The two-step model of mouse skin carcinogenesis uses 7,12-dimethylbenz[a]anthracene (DMBA*) as an initiator, followed by 12-O-tetradecanoylphorbol-13-acetate (TPA) as a promotor (1). This established model continues to be used to determine the molecular and
•Abbreviations: DMBA, 7,12-dimethylbenz [a] anthracene; TPA, 12-0-tetradecanoyl-phorbol-13-acetate; PCR/RFLP, polymerase chain reaction/ restriction fragment length polymorphism. cellular mechanisms involved in chemical and radiation carcinogenesis and to develop methodology for less defined situations. The first step in this model, the formation of DMBA-DNA adducts, results in characteristic mutations (4) . Mutations in the 61st codon of the c-Ha-ras gene are the most frequent mutations documented with this chemical initiating agent (5, 6 ). An accepted hypothesis is that the activating ras mutations cause alterations in the ras pathway that allow the clonal expansion of mutant cells under the influence of TPA (7) . TPA has been shown to induce a mitogenic response in some basal keratinocytes while inducing terminal differentiation in others (8) . It has been proposed that the activating mutations cause cells to remain in a proliferating state and resist terminal differentiation (9) . Co-culture of cells with activated 61st codon c-Ha-ras and normal keratinocytes shows a dose dependent outgrowth of colonies with TPA promotion (10) .
Three different 61st codon mutations have been noted in papillomas that eventually appear using the DMBA/TPA protocol. The majority (94%) of the papillomas have an A to T mutation in the 2nd position of 61st codon (T2). This mutation has been detected very early after initiating treatment (11). Rarely found are A to G mutations in the second position of the 61st codon (G2) (4%) and the A to T mutations in the 3rd position (T3) (2%) (6) .
An increased frequency of the T2 mutations soon after DMBA initiation, either by differential adduct formation or selective repair, is a possible explanation for the preponderance of papillomas with this mutation. Another possible explanation is a growth advantage for cells with the T2 mutation over the other mutations during promotion with TPA. Quantitating the specific c-Ha-ras mutations during early phases of tumor promotion might differentiate between these two possibilities. Although 61st codon mutations have been detected prior to papilloma development, no determination of the relative frequency of these three specific mutations has been made early in tumorigenesis. In this work we describe quantitation of these specific 61st codon c-Ha-ras mutations in mouse epidermis after initiation with DMBA and during the early stages of TPA promotion prior to the development of visible benign papillomas.
Materials and methods

Treatment of animals
The two-step mouse skin model of DMBA initiation followed by TPA promotion was used. For the dose-response/time dependence data, 5-weekold female CD-I mice (Charles River) were topically treated on shaved dorsal skin with 5 ug (20 nmol), 50 ug (200 nmol) and 200 ug (800 nmol) of the initiator DMBA (Sigma) in 200 ul of acetone followed by TPA promotion (Chemicals for Cancer Research, Chanhassen, MN) at 10 (ig (17 nmol) once per week starting 1 week after DMBA (12) . Two mouse skins were harvested and the epidermis was separated from dermis by heat shock (13) before being pooled into one sample. In a second study, the dose of 50 ug of DMBA (14) was used to make triplicate samples for each treatment group and harvest time. Four groups were studied including untreated animals, TPA promotion only, DMBA initiation only, and DMBA plus TPA. Samples were taken at various times for up to 12 weeks.
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DNA purification and fragmentation
DNA was purified by proteinase K and RNase treatment, followed by phenol/ chJoroform/isoamyl alcohol extractions (15) . High molecular weight DNA was precipitated, dissolved in water, and quantitated by spectrophotometry. DNA was digested at 37°C for 3 h with 5 units PstV\ig DNA and 5 units HindUVpg, DNA at a concentration of 0.2 |ig DNA/|il.
Primers
Based on published sequence (16) , first stage primers were chosen to amplify the same region of exon 2 of mouse c-Ha-raj for the detection of all three mutations.
Stage 1 Upstream Primer-5' CTGTGAATTCTCTGGTCTGAGGAG 3' (bp 244-267).
Stage 1 Downstream Primer-5' TAGGTGGCTCACCTGTACTG 3' (bp 491-510). Second stage primers were different for the different assays. For both 61st codon mutation assays, 2nd position A to T (T2) and second position A to G (G2).
Stage 2 Upstream Primer-5' CTAAGCCTGTTGTTTTGCAGGAC 3' (bp 302-322).
Stage 2 Downstream Primer-5' GGAACTTGGTGTTGTTGATGGC 3' (bp 455-475). For detection of the third position A to T (T3) mutation of the 61st codon, primers were designed to remove Mali! sites found in both mutant and wildtype alleles and therefore produce a longer mutation specific AVaW-digestion product (mismatches underlined).
Stage 2 Upstream Primer-5' TGGTCATTGATGGGGAGACGTG (bp 739-760).
Stage2 Downstream Primer-5' TGTACTGGTCCCGCGTGG(bp805-822).
Nested PCR/RFLP protocol
The nested PCR/RFLP protocol (17) produces a non-radiolabeled PCR product of 267 bp in the first stage of the assays for the three mutations A single radiolabeled band of 176 bp is made in the second stage of the T2 and G2 assays. When double stranded products from the last extension are digested with Xba\ (for T2) or Taql (for G2), only the products from the template with mutant 61st codons are digested. Digested products form a doublet of 91 and 85 bp for T2 and 90 and 86 bp for G2. In the T3 assay, the second stage double stranded PCR product of 84 bp forms specific bands of 52 and 32 bp after NlaWl digestion (Figure 1 ). The first stage of PCR includes 500 ng of DNA with 2 mM Mg into preheated DNA mix. Initial denaturation was 2 min at 97°C, followed by 14 cycles of 1 min at 97°C and 6 min at 67°C with auto-extension of 30 s/cycle after 10 cycles, and final extension of 20 min at 67°C. Minor modifications were made for the T3 assay. In stage two the cycles were increased to 17, with annealing temperature of 60°C and [ 32 P]dCTP increased to 10 uTi/assay.
Diagnostic restriction fragmentation and separation of the fragments
The second stage product (10 Hi) was added with or without 10 units of mutation specific enzyme (Xba\, Taql or NlallT) into a total volume of 30 u.1 digestion buffer and incubated 3-15 h under oil. Aliquots of 8 |il of loading buffer were added and 10 (il loaded onto a 32 cm wide, 0.4 mm thick 1 XTBE/ D-600 vinyl gel (American Technologies). Electrophoresis was done for 6 h at 400 V. Gels were dried for 30 min at 80°C.
Phosphor imaging and processing of data
The gel was exposed to a phosphor imaging plate (Molecular Dynamics) for 48-64 h for the mutation specific band and 1-3 h for the undigested portion of the PCR product. Diagnostic product was quantitated with ImageQuanr 1 (Molecular Dynamics) software using a background subtraction from each lane, and normalized to the undigested PCR product. Comparison to the standard curve yielded a number representing the copies of mutant alleles in a sample of 500 ng of DNA. Total DNA recovered from an epidermis, 400 Hg in mice receiving TPA treatment, was used as a factor to convert mutant copies/500 ng to mutant copies/epidermis. 
Assembly of control plasmids
Plasmid pCRRAST2 carries the A to T mutation in the 2nd position of the mouse 61st codon. For the construction of this plasmid, CarB cell line (18) DNA was amplified by PCR with upstream c-Ha-ras primer (bp 385-905) 5' AGAGAATTCCCGCTGTAGAAGCTATGAC 3' and downstream pnmer (bp 936-964) 5' CACAGAATTGACACGGAAGCTTCCTCACG 3' and inserted into PCRII (Invitrogen) vector by TA cloning. Plasmid pCRRASG2 carries the 2nd position A to G mutation at the 61st codon. This plasmid was generated by two-stage PCR amplification of tumor DNA known to contain this mutation before being inserted into PCRII by TA cloning. The first stage was identical to that for the pCRRAST2 plasmid. The second stage used inside upstream primer (bp 644-667) 5' CTGTGAATTCTCTGGTCTGAGGAG 3' and downstream primer (bp 930-953) 5' CACGGATCCTTCTCTACGTGTG-CC 3'. Plasmid pCRRAST3 carries the A to T mutation in the third position of the 61st codon Tumor DNA containing this mutation was amplified by the same nested PCR primers as used for pCRRASG2 and inserted into the PCRII by TA cloning. The sequence of the plasmids was confirmed by DNA sequencing and was shown to possess not only the correct mutation but also c-Ha-raj sequence identical to genomic sequence both upstream and downstream to the nested primers used in the assay.
Standard curves for assay sensitivity and specificity /".srl/PvuII-digested plasmids for each mutation were diluted with Pstl/HindlUdigested genomic DNA from untreated epidermis at a ratio of 1 mutant : 1 wild-type allele and assayed for the mutant gene dose (17) Standards for each mutation assay were compared to the non-assayed mutations for determination of specificity. To account for day to day variations in the PCR, plasmid dilutions were included as a standard with each set of PCR reactions. A sequencing size gel, which included samples from all various treatments and harvest times, was run and analyzed with the standard curve to control for gel to gel variations.
Statistical analysis
Program MinSQ II, Version 1.0 (Micromath, Salt Lake City, Utah) was used to fit the data by least squares to the exponential equation in the form v = exp (i + gt) where y = mutant copies, ( = time in weeks, / = initial mutations, and g = growth advantage under TPA promotion conditions. The correlation coefficient, r, for the fit of the data points to the exponential equation was calculated using the indicated program.
Results
Assays for the three 61st codon mutations of c-Ha-ras
Using diluted plasmids for the three mutations and biological samples from the pilot initiation/promotion study, the three nested PCR/RFLP assays were developed as shown in Figure  1 . A phosphor imaged D-600 poly vinyl gel (Figure 2) shows the characteristics of dilutions of these plasmid standards (T2, G2 and T3). Weak diagnostic radioactive bands were observed with untreated epidermal DNA for all three mutations before UlTma© was introduced into the protocol. Although they were greatly reduced in the assays using UlTma© and low nucleotide concentration, they remained a problem particularly in the G2 assay. Further testing showed these bands detected in the G2 assay were formed during the assay. Digestion of the genomic DNA with the mutation-specific enzyme Taq\ before the assay destroyed pre-existing mutations, but no reduction of this band using DNA from untreated animals could be seen with digestion (data not shown).
Quantitation of the dilutions of mutant plasmids from 500 copies per assay to 15 copies (1 mutant copy per 10 4 wildtype copies) is shown in Figure 3 for all three assays. Fresh dilutions of these standards were processed each time along with a set of biological samples. The T2 assay (Figure 2) had the least background with the control sample for the 85 bp band and this band was therefore used to quantitate this mutation. The slope of the line changed below 15 copies (Figure 2, Figure 3A) . All values for mutant copy numbers were determined by reading directly off a line much like the line shown in Figure 3A . Using the lower 86 bp band in the G2 assay (Figure 2, Figure 3B ), the 15 copy sample (1 mutant per 10 4 wild type) was not reliably higher than control. The T3 mutation assay had the disadvantage that the diagnostic enzyme NlaTU cut the PCR band into four small pieces. Therefore primers were included in the second stage of this Figure 2 was exposed to a phosphorimaging plate and analyzed for integrated volume. For each assay, the diagnostic band minus background was normalized to the wild-type band and the relative volumes plotted against mutant copies in the sample. Newly generated dilutions were assayed with each complete set of biological samples and used as a standard curve to convert radioactive volume to mutant copy number. The inset shows the shape of the curve at the most sensitive range. The most dilute positive sample (15 mutant copies) represents a ratio of 1 mutant copy per 10 4 wild-type alleles.
T3 assay to remove two NlaUl sites and leave only the mutation specific site (Figure 1 ). For each mutation assay, no cross-reactivity occurred with 500 copies of the other mutant plasmids (Figure 2 ).
Time-course study for T2 mutations in the epidermis of mice initiated with different doses ofDMBA and promoted with TPA
Before a DMBA dose was chosen for performing a more extensive biological study of DMBA initiation and TPA promotion, a pilot experiment at three dose levels of DMBA was performed. Two subcarcinogenic dose levels (14) Figure 4 shows the dose-response of the 61st codon second position A to T mutation (T2) in the epidermis taken at 8 and 12 weeks (after 7 and 11 weeks of weekly TPA promotion). This dose response was also seen at 4 weeks (data not shown). The higher subcarcinogenic dose of 50 |ig (200 nmol) of DMBA was chosen to study the effects of TPA promotion on expansion of the three mutant c-Ha-ras mutant copies in the following experiments.
Time-course for the CTA (T2) 61st codon mutation of c-Ha-ras after DMBA initiation and TPA promotion
Three independent sets of epidermal DNAs that included all treatment groups and times were processed along with standards. The assays were run on gels at the same time to allow for day to day, or gel to gel variations. Figure 5 shows the data for this mutation as a scatter plot to visually demonstrate the variability between the samples. Samples that showed no mutant copies have been displaced slightly on both axes to show all the samples. Samples of epidermal DNA, derived from mice that were both initiated with 50 ng (200 nmol) DMBA and promoted with TPA, showed an outgrowth of the A to T mutation in the 2nd position of the 61st codon of c-Hz-ras (T2). All data points for the untreated animals, TPA only, and DMBA only are shown to demonstrate the Figure 6 shows the data for the G2 mutation plotted in the same manner as the T2 data. No consistent increase in G2 mutations could be seen with time. In addition, no consistent difference in G2 mutation levels was observed between treatment groups over the course of the 12 week experiment. Figure 7 shows the data for the T3 mutation plotted in the same manner as the graphs for the other two mutations. Some of the DMBA plus TPA samples showed mutant copies above the background by 5 and 6 weeks with outgrowth clear in the group at 12 weeks. At 12 weeks an average of ~ 40 copies/ 500 ng sample or 3X10 4 mutant alleles/epidermis was reached. A best-fit line in the form y = exp (/ + gf) where y = mutant copies,;' = mutations at initiation, g = growth rate under TPA conditions and t = time in weeks for the T3 mutation is y = exp (0.301 + 0.276 /)• The correlation coefficient, r, for the fit of the line is 0.875. Fig. 7 . Scatter plot of CAT (T3) mutant alleles of the 61st codon of c-Ha-ras versus the harvest time in weeks after initiation with DMBA (50 Hg) and weekly TPA (10 ug) promotion started one week after initiation. A set of samples, representing the full time course and all treatment groups, and a T3 plasmid standard curve were amplified and run together on a 1XTBE 8 5%/D-600 sequencing size gel. The same Stage I PCR product that was assayed for T2 and G2 mutations entered a Stage n PCR amplification with different primers. Digestion of the second stage 84 bp product with MaNI produced a 52 bp diagnostic band that was quantitated by phosphorimaging, and converted to mutant copy number by comparison to the standard curve. The log of mutant copies was plotted vs. harvest time in weeks after DMBA initiation for the various treatments. Results shown are derived from three independent experiments. Samples that have a calculated mutant copy number of zero have been displaced to see all the data points. The exponential best-fit line calculated by least squares is shown.
Time-course for the CGA (G2) 61st codon mutation ofc-Ha-ras after DMBA initiation and TPA promotion
Time-course for the CAT (T3) 61st codon mutation ofc-Ha-ras after DMBA initiation and TPA promotion
Discussion
Historically, clonal expansion of 'initiated' cells has been the working hypothesis and explanation for the effects of tumor promoters during carcinogenesis (19) . In this study, the clonal expansion of cells carrying two different mutations in the 61st codon of c-Ha-ras (T2 and T3) was quantitated with a nested PCR/RFLP assay during TPA promotion in mouse skin initiated with DMBA. The best fit lines of these data are exponential curves as would be expected with the fraction of mutant cells expanding in comparison to wild-type cells. This clonal expansion was seen only with the group of mice that was both initiated with DMBA and promoted with TPA, fitting the definition of promotion. These cells according to the two-stage model of mouse carcinogenesis would be expanding under the influence of TPA to become clones of initiated cells seen as frank papillomas (7).
The effects of TPA on epidermal basal cells in culture is complex and includes both a stimulation of proliferation of one subgroup of cells and an induction of terminal differentiation in another subgroup of cells (8) . Harvey (Ha) sarcoma virusinfected cells when induced to differentiate are blocked at an early stage of maturation and respond to TPA with a reversion to a less mature state (9) . Purified mutant Ras proteins have been shown to have reduced GTPase activity that maintain the Ras/GTP complex in a constantly activated form (20,21). Thus TPA promotion, which results in clonal expansion of mutant c-Ha-ras cells in the skin, could be characterized by disruption of the normal signaling in the ras pathway, increased proliferation of cells with mutant c-Ha-ras alleles and/or increased terminal differentiation of normal cells.
With this DMBA/TPA protocol, we quantitated ~8X 10 5 T2 mutant alleles/epidermis at 12 weeks and only 3X10 4 T3 mutant alleles/epidermis at the same time. This is consistent with the reported preponderance of the T2 papUlomas (94%) and the low number of T3 papillomas (2%) eventually observed (6) . Two explanations can be proposed for the preponderance of A to T mutations in the second position 61st codon (T2) of c-Ha-ras seen in papillomas after DMBA/TPA treatment. One possibility would be increased frequency of T2 mutations soon after DMBA initiation as a result of either selective DNA adduct formation or repair. We have used the 'f component of the exponential best-fit lines to estimate that ~390 cells possessed the T2 (CTA) mutation and a similar number possessed the T3 (CAT) mutation in the original DMBA treatment area. This area contains ~2.2X 10 7 cells. The relative initiation frequencies of T2 and T3 mutations ('«' = 0.305 and 0.301, respectively) may not be correct because of the variability of the biological data, the sensitivity of the assays, and the necessity to extrapolate points back in time. Therefore, we cannot conclude that the T2 and T3 mutations are formed at the same rate during the initiation process.
Another explanation for the abundance of T2 mutations in papillomas is a selective growth advantage for cells with this T2 mutation over those with a T3 mutation. The relative strengths of the 'g' components from the statistical best-fit lines for the T2 and T3 growth curves suggest a growth rate during TPA promotion greater for the cells with the T2 mutation than for those with the T3 mutation. Because the best-fit equations include initial mutation frequencies that are no higher for T2 mutation than the T3, the effect of the selective growth advantage reflected by the 'g' components (0.552 for T2 compared to 0.276 for T3) could be sufficient to explain both the increased T2 clonal expansion and the preponderance of cells with the T2 mutation in papillomas. Interestingly, this suggested difference of in vivo growth rate corresponds closely to in vitro data using the relative transforming activity of DNA for the 61st codon mutations. Plasmid DNA that codes for the 61st codon leucine Ras (T2 mutation) produced 4.5 times more foci/ng DNA than DNA that codes for the 61st codon histidine Ras (T3 mutation) (22) . However, all 61st codon mutant Ras proteins displayed comparable reduced rates of GTP hydrolysis (22) showing the complexity of the factors in this proliferation/differentiation pathway. Our methods for sensitive measurements of clonal expansion might be used in vitro to help define the complex interactions of mutant Ras with upstream regulators as well as downstream effectors particularly in co-culture where interactions between cells more closely model the animal.
To detect the mutations before the appearance of tumors, we needed sensitive and specific assays for each of these mutations. The PCR/RFLP (23) method was chosen because of its specificity. The assay was modified by the addition of a nested PCR step (24) . Another modification is the use of the editing polymerase UlTma© (Perkin Elmer) under conditions of low nucleotide concentration (4 ^M) during the first stage to amplify the wild-type and mutant c-Ha-ras alleles and radiolabeling by incorporation of [ 32 P]nucleotides in the second stage with Stoffel© fragment polymerase (Perkin Elmer), which has no 5' to 3' exonuclease (25) . These improvements create very complete, highly labeled copies of both alleles with reduced background and reduced extraneous bands in the lane. Standard plasmid dilutions for the three mutations supplied a reference for converting diagnostic band intensity to number of mutant copies and allowed for comparisons between different mutations. Quantitating wild-type copies present in this nested PCR/RFLP assay proved to be a helpful index (26) to compensate for differences in PCR efficiency, quality or quantitation of the DNA as well as pipetting and loading differences.
False positive bands seen with samples from untreated mouse skin were a complicating factor in the nested PCR/RFLP assay for the CGA 61st codon mutation (G2). Predigestion of sample DNA with the diagnostic enzyme Taql demonstrated that these products were formed during the PCR amplification. Taql may have a lower level of sequence specificity than the restriction enzymes used to identify the other mutations. More likely these products represent the errors by Taq polymerase and by the 3' to 5' exonuclease proofreading enzyme UlTma. PCR fidelity is affected by both insertion of a wrong base and further extension from that base. The fidelities of the different polymerases vary in each step and under various conditions for various mismatches (27) . A lack of extension from a mismatch or from a sequence related termination would produce a false positive product. These can be seen on gels, in lanes with and without digestion, for all three mutations at high cycle number and high specific radioactivity (Figure 2 ). The presence of both diagnostic bands at much higher levels in the G2 assay suggests extension of a G misinsertion. In general G:T mismatches extend most efficiently, while A:A mismatches extend least efficiently (27) . The G:T mismatch occurs in the G2 assay on the extension of the antisense strand of the wild-type allele. The less efficiently extended A:A mismatch causes less background as seen in the more sensitive T2 and T3 assays.
One would expect to see an almost equal level of the G2 mutation to the T3 mutation because of the near equal frequency of papillomas with those two mutations (6) . We think that with greater sensitivity we may have detected the G2 mutation in the epidermis during the 12-week experiment. Various laboratories have reported 61st codon c-Ha-ras mutations CGA(G2) in tumors after promotion without initiation in Sencar animals (28, 29) . This supports the hypothesis that cells with this mutation clonally expand under promotion with TPA. Harvest times as long as 60 weeks and extended periods of TPA promotion of up to 30 weeks used in these 'promotion without initiation' experiments would allow time for expansion of G2 mutations formed at a very low 'spontaneous' rate. Significant differences in susceptibility to skin carcinogenesis between CD-I mice used in our study and Sencar animals have been noted. Formation of the CGA 61st mutation during fetal development of Sencar animals has been hypothesized. Sencar animals may be defective in the repair of misinserted bases (29) .
We feel that this assay might be useful to compare different carcinogens that create 61st codon mutations for their mutation rate by a comparison of the V component of growth curves. This method can also be used to compare promoters to determine their relative strength by analysis of the 'g' component of the exponential curve. The nested PCR/RFLP method could be used in other carcinogenesis models where particular mutations are thought to expand under various promotion treatments or where different mutations have been suggested to act only during a particular stage, over particularly long periods of promotion, or where more than one promoter is 2556 thought to be effective. Initiation and promotion might be able to be estimated by the characteristics of the clonal expansion before tumors actually develop.
In summary, we have used a sensitive nested PCR/RFLP to quantitate CTA and CAT 61st codon mutant c-Ua-ras alleles in the early stages of mouse skin tumorigenesis using a DMBA/ TPA two stage protocol. Clonal expansion was shown for both the T2 and T3 mutation bearing cells during the 12 week experiment. TPA promotion appears to offer a sufficiently higher growth advantage to cells with a T2 mutation over those with a T3 mutation to account for the high frequency of the T2 mutation observed in papillomas formed by this method.
